From the Blood and Marrow Transplant Program (Z.D., Y.-B.C.), the Liver Center, Division of Gastroenterology (P.P.B., R.T.C.), and the Division of Infectious Diseases (M.T.S., M.K.M., S.T., E.L.H.), Massachusetts General Hospital, Harvard Medical School (Z.D., P.P.B., M.T.S., M.K.M., S.T., R.T.C., Y.-B.C., E.L.H.), and Day Zero Diagnostics (M.R.A.S., M.H.H.) - all in Boston.
N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.
Fecal microbiota transplantation (FMT) is an emerging therapy for recurrent or refractory infection and is being actively investigated for other conditions. We describe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.
粪便微生物群移植（FMT）是一种新兴的治疗复发性或难治性感染的方法，目前正在积极研究用于其他疾病。我们描述了两例在两项独立临床试验中接受 FMT 后发生产超广谱β-内酰胺酶（ESBL）的患者；通过基因组测序，这两例均与同一供体粪便相关。其中一名患者死亡。需要加强供体筛查，以限制可能导致不良感染事件的微生物的传播，并保持警惕，以确定 FMT 在不同患者人群中的益处和风险。
